Previous 10 | Next 10 |
home / stock / xphyf / xphyf news
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / November 19, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the appointment of Mr. Joseph Meagher as Chief Financial Officer of the Company. Mr. Meagher is a Charter...
Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 pre...
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infec...
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / November 3, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the...
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator at the leading-edge of the life science industry, has released updated information regarding its drug formulation and development focus. The company is continuing its focus on advancing multiple generi...
Rotigotine transdermal skin patch optimization and pivotal study planning underway Rotigotine patch manufacturing, sales and marketing in preparation Cannabinoid oral dissolvable film (ODF) programs advanced, CBD ODF ready for pilot study Prioritization of additional near-ter...
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator at the leading-edge of the life science industry, announced that it has extended its investor relations consulting agreement with Knox Communications Inc. (“KCI”) and M. Davis & Ass...
VANCOUVER, BC / ACCESSWIRE / October 8, 2021 / XPhyto Therapeutics Corp. ( CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT ) (" XPhyto" or the" Company ") announces it has entered into extensions to investor relations consulting agreements with each of Knox Communications Inc. (" KCI ") and M. Davis &...
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug diagnostics, delivery and new active pharmaceutical ingredient investment opportunities, including: rapid, low-cost infectious disease test (EU approved rapi...
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator at the leading-edge of the life science industry, announced that the market launch of its 25-minute COVID-19 PCR Test COVID-ID Lab has been a success. The company unveiled the project at test centers i...
News, Short Squeeze, Breakout and More Instantly...
XPhyto Therapeutics Corp Company Name:
XPHYF Stock Symbol:
OTCMKTS Market:
VANCOUVER, BC / ACCESSWIRE / October 3, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT), announces that Per Thoresen and Peter Damouni have resigned as directors of the Company. The Company would like to thank Mr. Thoresen and Mr. Damouni for their c...
VANCOUVER, BC / ACCESSWIRE / September 28, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) is pleased to announce that, further to its news releases dated August 4 and August 28, 2023, the Company has closed the second tranche of its non-brokered pri...
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / August 4, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce a non-brokered private placement of u...